Procarta is uniquely developing a new class of antibacterials to become agents of first resort against the rising threat of drug-resistant bacterial infections ('superbugs') for which it has sought IP protection. The company's technology platform allows Procarta to rapidly design proprietary antibacterials to treat extant and emerging infections with Narrow- or Broad-spectrum activity. Procarta is seeking fresh investment to develop its platform or partnering opportunities to realise its potential.

Procarta Biosystems Ltd
Norwich Bio-Incubator
Norwich Research Park
Colney Lane, Norwich, UK
NR4 7UH
Tel: +44 (0) 1603 450960
Fax: +44 (0)1603 450778
Email: info@procartabio.com

SCIENCE AND TECHNOLOGY

Dr. Michael McArthur
Tel: +44 (0) 1603 450960
Email: mmcarthur@procartabio.com

CHAIRMAN

Dr. David Knowles
Email: dknowles@procartabio.com